| PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer E Castro, N Romero-Laorden, A Del Pozo, R Lozano, A Medina, J Puente, ... Journal of Clinical Oncology 37 (6), 490-503, 2019 | 332 | 2019 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 134 | 2023 |
| BRCA2 and other DDR genes in prostate cancer P Nombela, R Lozano, A Aytes, J Mateo, D Olmos, E Castro Cancers 11 (3), 352, 2019 | 97 | 2019 |
| Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer R Lozano, E Castro, IM Aragón, Y Cendón, C Cattrini, PP López-Casas, ... British journal of cancer 124 (3), 552-563, 2021 | 86 | 2021 |
| Current treatment options for metastatic hormone-sensitive prostate cancer C Cattrini, E Castro, R Lozano, E Zanardi, A Rubagotti, F Boccardo, ... Cancers 11 (9), 1355, 2019 | 78 | 2019 |
| Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer R Lozano, DC Salles, S Sandhu, IM Aragón, H Thorne, F López-Campos, ... European Journal of Cancer 147, 74-83, 2021 | 48 | 2021 |
| Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus … N Romero-Laorden, R Lozano, A Jayaram, F López-Campos, MI Saez, ... British Journal of Cancer 119 (9), 1052-1059, 2018 | 38 | 2018 |
| Clinical applications of molecular biomarkers in prostate cancer F Couñago, F Lopez-Campos, AA Díaz-Gavela, E Almagro, ... Cancers 12 (6), 1550, 2020 | 37 | 2020 |
| HSD3B1 (1245A> C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two … DJ Khalaf, IM Aragón, M Annala, R Lozano, S Taavitsainen, D Lorente, ... Annals of Oncology 31 (9), 1186-1197, 2020 | 27 | 2020 |
| A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia PJ Fonseca, A Carmona-Bayonas, IM García, R Marcos, E Castañón, ... British Journal of Cancer 114 (11), 1191-1198, 2016 | 21 | 2016 |
| Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving … D Olmos, D Lorente, D Alameda, C Cattrini, N Romero-Laorden, ... Journal of Clinical Oncology 41 (16_suppl), 5003-5003, 2023 | 14 | 2023 |
| Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations AO Sokolova, CH Marshall, R Lozano, R Gulati, EM Ledet, N De Sarkar, ... The Prostate 81 (16), 1382-1389, 2021 | 14 | 2021 |
| Value of early circulating tumor cells dynamics to estimate docetaxel benefit in metastatic castration-resistant prostate cancer (mCRPC) patients R Lozano, D Lorente, IM Aragon, N Romero-Laorden, P Nombela, ... Cancers 13 (10), 2334, 2021 | 13 | 2021 |
| Treatments outcomes in histological variants and non-urothelial bladder cancer: results of a multicenter retrospective study N Epaillard, P Parent, Y Loriot, P Lavaud, EB Vera-Cea, ... Frontiers in oncology 11, 671969, 2021 | 11 | 2021 |
| Association between second progression-free survival (PFS2) and overall survival in metastatic castration-resistant prostate cancer D Lorente, E Castro, R Lozano, J Puente, N Romero-Laorden, ... European urology 77 (6), 763-766, 2020 | 10 | 2020 |
| A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot … JL García, R Lozano, I Misiewicz-Krzeminska, J Fernández-Mateos, ... Clinical and Translational Oncology 19, 1350-1357, 2017 | 10 | 2017 |
| Risk prediction tools available for germline BRCA1/2 mutations underperform in prostate cancer patients L Oliva, R Lozano, C Llácer, I Aragón, BI Pajares, MI Sáez, ... European Urology Oncology 4 (2), 315-318, 2021 | 8 | 2021 |
| Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma P Parent, E Auclin, A Patrikidou, L Mezquita, N Martínez Chanzá, ... Cancers 15 (4), 1066, 2023 | 5 | 2023 |
| Prognostic score and benefit from abiraterone in first-line metastatic, castration-resistant prostate cancer D Lorente, C Llacer, R Lozano, G de Velasco, N Romero-Laorden, ... European Urology 80 (5), 641-649, 2021 | 5 | 2021 |
| Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study V Conteduca, D Wetterskog, E Castro, E Scarpi, N Romero-Laorden, ... European Journal of Cancer 152, 49-59, 2021 | 5 | 2021 |
